These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16491719)
41. Post-antibiotic effect (PAE) of moxifloxacin in multidrug-resistant Stenotrophomonas maltophilia. Korakianitis I; Mirtsou V; Gougoudi E; Raftogiannis M; Giamarellos-Bourboulis EJ Int J Antimicrob Agents; 2010 Oct; 36(4):387-9. PubMed ID: 20674284 [No Abstract] [Full Text] [Related]
42. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Lichtenstein SJ; Wagner RS; Jamison T; Bell B; Stroman DW Adv Ther; 2007; 24(5):1098-111. PubMed ID: 18029337 [TBL] [Abstract][Full Text] [Related]
43. Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model. Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ J Ocul Pharmacol Ther; 2008 Feb; 24(1):1-7. PubMed ID: 18370872 [TBL] [Abstract][Full Text] [Related]
44. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Scoper SV Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691 [TBL] [Abstract][Full Text] [Related]
45. Moxifloxacin-dependent Torsades de Pointes. Tiryakioğlu SK; Tiryakioğlu O; Aktürk F; Mehmetoğlu E; Kumbay E Anadolu Kardiyol Derg; 2011 Sep; 11(6):560-2. PubMed ID: 21827995 [No Abstract] [Full Text] [Related]
46. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787 [TBL] [Abstract][Full Text] [Related]
47. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections]. Iakovlev SV; Polushkina NR; Iakovlev VP Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197 [No Abstract] [Full Text] [Related]
48. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Barry AL; Fuchs PC; Brown SD Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024 [TBL] [Abstract][Full Text] [Related]
49. [Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (Vegamox 0.5% ophthalmic solution]. Watanabe M; Ishizuka K; Ikemoto T Nihon Yakurigaku Zasshi; 2007 May; 129(5):375-85. PubMed ID: 17507775 [No Abstract] [Full Text] [Related]
50. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978 [TBL] [Abstract][Full Text] [Related]
51. Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery. Jensen MK; Fiscella RG Am J Health Syst Pharm; 2006 Sep; 63(17):1637-40. PubMed ID: 16914634 [No Abstract] [Full Text] [Related]
52. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770 [TBL] [Abstract][Full Text] [Related]
53. Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions. Prescrire Int; 2009 Oct; 18(103):207. PubMed ID: 19882788 [TBL] [Abstract][Full Text] [Related]
54. Ophthalmic infections and their anti-infective challenges. Alfonso E; Crider J Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307 [TBL] [Abstract][Full Text] [Related]
55. Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery. Bucci FA; Amico LM; Evans RE Eye Contact Lens; 2008 Jan; 34(1):39-42. PubMed ID: 18180682 [TBL] [Abstract][Full Text] [Related]
56. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Ginsburg AS; Lee J; Woolwine SC; Grosset JH; Hamzeh FM; Bishai WR Antimicrob Agents Chemother; 2005 Feb; 49(2):853-6. PubMed ID: 15673788 [TBL] [Abstract][Full Text] [Related]
57. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Roberts CH; Smith C; Breen R; Gadhok R; Murphy M; Aryee A; Cropley I; Bhagani S; Hopkins S; Lipman M Int J Tuberc Lung Dis; 2011 Sep; 15(9):1275-6. PubMed ID: 21943863 [No Abstract] [Full Text] [Related]
58. Moxifloxacin prophylaxis in neutropenic patients. von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172 [TBL] [Abstract][Full Text] [Related]